Online inquiry

IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ61MR)

This product GTTS-WQ61MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets H1-0 gene. The antibody can be applied in Glioblastoma multiforme (GBM) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_005318.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3005
UniProt ID P07305
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ61MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ2468MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, AMG 181(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG 181
GTTS-WQ9203MR IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IMMU-106
GTTS-WQ9467MR IVTScrip™ mRNA-Anti-C5AR1, IPH-5401(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IPH-5401
GTTS-WQ7353MR IVTScrip™ mRNA-Anti-VTCN1, FPA-150(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA FPA-150
GTTS-WQ13789MR IVTScrip™ mRNA-Anti-S, REGN-10933(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA REGN-10933
GTTS-WQ12285MR IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MSB-0010718C
GTTS-WQ13224MR IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PF-05082566
GTTS-WQ8048MR IVTScrip™ mRNA-Anti-F, H1H3592P3(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA H1H3592P3
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW